Silexion Therapeutics holds reconvened shareholder meeting after quorum shortfall
SLXN•Silexion Therapeutics shareholders approved an increase of 500 million authorized ordinary shares and a 1-for-24 reverse split at a meeting reconvened on October 26, 2026.
1. Shareholder approvals
At its reconvened extraordinary meeting on October 26, 2026, Silexion Therapeutics shareholders approved a 500 million-share increase in authorized ordinary shares. The amendment took effect that day, raising the authorized total from 15.9 million to 515.9 million shares.
2. Reverse split terms
The board selected a 1-for-24 reverse split, within the previously authorized range of 1-for-15 to 1-for-25. It will cover issued and outstanding shares as well as authorized but unissued shares, and increase par value from US$0.135 to US$3.24.
